Supporting KalVista’s NDA Submission for a Novel HAE Treatment Case Study Supporting KalVista’s NDA Submission for a Novel HAE Treatment To accelerate the first oral therapy for hereditary angioedema (HAE), KalVista Pharmaceuticals partnered with Certara…Danielle PillsburyNovember 12, 2025
Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation Publication Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation This study demonstrates how model-informed approaches can improve dose selection decisions when direct clinical comparisons…CertaraNovember 5, 2025
Delivering on Deadline: Navigating Regulatory Submissions with Pharmacometrics Insights On-Demand Webinar Delivering on Deadline: Navigating Regulatory Submissions with Pharmacometrics Insights Watch this on-demand webinar to learn how pharmacometrics supports NDA, BLA, and global regulatory submissions.…CertaraNovember 3, 2025
Establishing Immune Correlates of Protection Against Respiratory Syncytial Virus Infection to Accelerate Vaccine Development: A Model-Based Meta-Analysis Publication Establishing Immune Correlates of Protection Against Respiratory Syncytial Virus Infection to Accelerate Vaccine Development: A Model-Based Meta-Analysis Bridge across studies with Model-based Meta Analysis, incorporating broader data & synthetic patients to enhance…CertaraOctober 31, 2025
AAPS Webinar – Pediatric Drug Development: Why It’s Critical to Submission Strategy and How Modeling, Regulatory, and Clinical Insights Shape Success On-Demand Webinar AAPS Webinar – Pediatric Drug Development: Why It’s Critical to Submission Strategy and How Modeling, Regulatory, and Clinical Insights Shape Success Learn how model-informed drug development, clinical pharmacology, and regulatory strategy support successful pediatric drug development…CertaraOctober 21, 2025
Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer Case Study Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer Certara’s support enabled fast-track FDA oncology approval 2025 for Sunvozertinib, a breakthrough NSCLC therapy targeting…CertaraOctober 2, 2025
Certara Launches DIDB® Concomitant Meds Navigator, Extending Leadership in Drug Interaction Science Announcement Certara Launches DIDB® Concomitant Meds Navigator, Extending Leadership in Drug Interaction Science Meet DIDB Concomitant Meds Navigator—an evidence-based tool to identify contraindicated or monitored co-medications and manage…CertaraSeptember 22, 2025
FAQs on Developing EMA Policy 0070 Submissions Blog FAQs on Developing EMA Policy 0070 Submissions This blog answers audience questions posed during our RAPS webinar, How to Plan for a…CertaraSeptember 15, 2025
The Top 10 Things You Need to Know About ADNCA Datasets Guide The Top 10 Things You Need to Know About ADNCA Datasets Learn how ADNCA datasets can modernize non-compartmental analysis: enhanced compliance, automations, and faster PK data…CertaraSeptember 11, 2025